SOURCE: Revolutions Medical Corp.

Revolutions Medical Corp.

February 03, 2010 07:00 ET

RevMed Gives Operational Update and Outlook in Open Letter to Shareholders

CHARLESTON, SC--(Marketwire - February 3, 2010) - Revolutions Medical Corporation ("RevMed" or the "Company") (OTCBB: RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, today provided a recap of important milestones achieved in 2009 and offered a corporate outlook for 2010 through the following open letter to shareholders:

From the Desk of RevMed CEO Ron Wheet

Dear RevMed Shareholders,

This last year was truly a watershed one for RevMed, and it has brought us a great distance towards the commercial launch of the RevVac safety syringe, and the subsequent launch of our revolutionary suite of color MRI software. Consistent with our commitment to proactive investor communication, we would like to recap the past year and provide a brief outlook for 2010.

Fiscal Year 2009

This last year saw horrific market conditions, a plague of business failures and consumers everywhere tightening their belts. Yet the medical industry continued to expand. Revolutions Medical not only weathered the storm but was successful in raising capital and meeting its short term operational objectives. We reached the tipping point of launching our two core recurring revenue business lines. We believe we have laid the foundation in 2009 to achieve profitability in our first full year of distribution and sales; we began the transition from a company developing products to one manufacturing and distributing potential market game-changers, and to a company poised to generate real revenue and earnings.

Looking briefly to 2008 and continuing through 2009 we have achieved the following:

    --  Ascended to the Over-the-Counter Bulletin Board and acquired 100%
        of Clear Image Acquisition Corporation, the developer of our MRI
        software technology

    --  To date, approximately $3 MM has been invested toward RevColor and
        Rev 3D MRI product development

    --  To date, approximately $3 MM  has been invested toward the RevVac
        Safety Syringe product development

    --  Received FDA 510K clearance for the RevVac safety syringe

    --  Launched the initial steps of RevVac manufacturing process for the
        3ml safety syringe

    --  Forged a distribution partnership with Libra International in South
        America -- the first of many targeted worldwide syringe markets

    --  Began cultivating relationships with more than 50 distributors
        worldwide and now will initiate the process of signing distribution
        agreements with those that fit our criteria to distribute our
        products

    --  Introduced the MRI suite of products on the imaging technology and
        software world stage at the Radiological Society of North America
        (RSNA) in Chicago

    --  Signed RevMed President Tom O'Brien, acclaimed pioneer in MRI
        sales/marketing and the former CEO of private and public medical
        companies, to a 3-year employment agreement

    --  Opened our new corporate office at:
               670 Marina Drive, Third Floor
               Charleston, SC 29492

    --  Appointed distinguished law firm Anslow & Jaclin, LLP as legal
        counsel, represented by firm partner Joseph M. Lucosky, Esq.

    --  Hired the accredited accounting firm Elliott Davis LLC

    --  Engaged Cirrus Financial Communications as our external Investor
        Relations Officer; for all investment-related inquiries please
        contact Cirrus Managing Partner Justin K. Davis at:
               (877) 307-RMCP (7627)
               Justin.Davis@CirrusFC.com

Fast Facts

Prior to our 2010 outlook and in response to investor inquiries, we would like to take this opportunity to reiterate some fundamental company information.

Capital Structure and Balance Sheet

    --  Basic shares outstanding: 33.1 MM

    --  Fully diluted shares outstanding: 43.2 MM

    --  Approximate float: 24.0 MM shares

    --  52-week range: $0.14 - $0.71

    --  No long term debt

Intellectual Property (IP)

RevMed has secured multiple design, technology and process patents, and has filed to receive many more -- we are confident that we enter the market substantially protected, and will only further secure our defense against competition in the months to come. To date, we can claim the following:

    --  Image Enhancement: 4 U.S. and 2 international patent applications
        filed

    --  Safety Syringe: 4 U.S. patents awarded and 7 international patent
        applications filed

    --  Blood Drawing Device: 1 U.S. patent awarded

Fiscal Year 2010

We are very optimistic about 2010, and below are some anticipated items/initiatives of note for the coming year:

    --  Sign up distributors nationally and worldwide

    --  License additional syringe manufacturers

    --  Integrate MRI tools into a delivery platform

    --  Receive validation of MRI tools with major teaching hospitals and
        experts in the various applicable fields of medicine

    --  Confirm additional MRI diagnostic applications such as Alzheimer's,
        concussion, cardiac disease and breast disease

    --  Negotiate agreements with other equipment manufacturers and
        value-added resellers

    --  Set up, packaging and quality assurance in Charleston, South
        Carolina

    --  Continue to expand family of safety syringes, blood drawing devices
        and other products in aesthetics, etc

    --  Continue to build management team, adding a Chief Technology
        Officer, International Sales Manager and others as appropriate

In closing, we would like to thank you all for your past support, continued interest, and in many cases, your dedication and patience. After years of research and development, we believe our vision will become reality in 2010. Never has health care been a more important issue, and the focus of the conversation is on increased safety at dramatically reduced cost. We feel that RevMed is perfectly positioned to capitalize on this vital need through our two immediate product line opportunities.

To be added to the Revolutions Medical investor email list, please email justin.davis@cirrusfc.com with RMCP in the subject line.

Become a RevMed fan and follow the Company on Facebook -- visit www.facebook.com/RevMed.

About Revolutions Medical Corporation (www.revolutionsmedical.com)

RevMed's products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.

Investor Resource Center

Fact Sheet: http://content.stockpr.com/rmcp/files/RMCP_-_Fact_Sheet_09-09-09.pdf

CEO Ron Wheet Audio Interview: http://ir.stockpr.com/revolutionsmedical/media-center/view/33/

RevVac Demo Video: http://www.revolutionsmedical.com/videos/revac_directions_final.wmv

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information